Search

Your search keyword '"Rispens, Theo"' showing total 867 results

Search Constraints

Start Over You searched for: Author "Rispens, Theo" Remove constraint Author: "Rispens, Theo" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
867 results on '"Rispens, Theo"'

Search Results

3. Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy

7. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

8. A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis

10. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: A nested case-control study

11. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses

13. Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines

14. Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands

15. Differences in IgG autoantibody Fab glycosylation across autoimmune diseases

16. The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees

18. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

20. Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases

22. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

23. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

26. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

27. Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication

28. Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients

29. Belimumab concentration measurements using a homologous anti-idiotype immunoassay

30. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

31. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: A nested case-control study

32. Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients

33. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

34. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease:A nested case-control study

35. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses

38. Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study

39. Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

40. Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection

41. Early model-based precision-dosing at home to guide adalimumab therapy

42. Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis

45. CD5L is a canonical component of circulatory IgM

46. Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment

47. Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

48. Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load

Catalog

Books, media, physical & digital resources